What does CalciMedica do?
CalciMedica, Inc. is a Nasdaq-listed clinical-stage biopharmaceutical company developing small molecules that inhibit calcium release-activated calcium, or CRAC, channels. It has no approved products or product revenue. Its thesis is that abnormal CRAC signaling drives both excessive immune activation and direct tissue injury across acute inflammatory and cardiopulmonary diseases.
The official investor profile centers on Auxora, intravenous zegocractin for hospitalized settings, and CM5480, an oral candidate for chronic use. Value therefore depends on clinical execution, regulatory progress, patents, and financing rather than recurring sales.
How is the company organized around one biological platform?
CalciMedica has no commercial segments; its practical units are development programs. Auxora supplies human safety and efficacy evidence from acute pancreatitis, COVID-19, acute kidney injury, and pediatric pancreatic toxicity. CM5480 extends the mechanism toward chronic cardiopulmonary treatment. The technology and pipeline page describes CRAC inhibition as both immunomodulatory and tissue-protective.
| Identity factor | Company-specific fact | Why it matters |
|---|---|---|
| Core platform | Selective inhibition of Orai1-containing CRAC channels | One mechanism may support multiple acute and chronic indications. |
| Lead asset | Auxora, intravenous zegocractin | Human clinical dataset anchors the platform’s credibility. |
| Next asset | CM5480, oral candidate in preclinical/IND-enabling work | Could broaden the model from episodic hospital use to chronic therapy. |
| Operating model | Small internal team plus CROs, consultants, and CMOs | Keeps fixed infrastructure limited but increases vendor dependence. |
How can CalciMedica create value before commercial revenue?
A pre-revenue biotech creates value by reducing scientific and regulatory uncertainty. CalciMedica funds development with equity, warrants, debt, and possible collaborations. Evidence, IND clearance, proof-of-concept results, pivotal-trial alignment, approval, and reimbursement are the milestones that can raise probability-weighted value before sales begin.
What would the eventual revenue model look like?
If a candidate is approved, CalciMedica could sell it directly, partner, or license regional rights. Its 2025 Form 10-K notes that commercial distribution is not established. Potential economics include product sales, upfront payments, milestones, royalties, or co-commercialization; none is assured.
Why is the cost structure dominated by research?
Manufacturing and much clinical execution are outsourced. Costs therefore concentrate in trial sites, CROs, drug supply, regulatory work, and specialized personnel rather than owned plants. Enrollment, protocol changes, manufacturing validation, and safety follow-up can still move cash requirements sharply.
| Value-chain stage | Current economics | Primary uncertainty |
|---|---|---|
| Discovery and preclinical | Cash outflow for pharmacology, toxicology, and formulation | Animal data may not translate to humans. |
| Clinical development | Largest prospective use of capital | Safety, enrollment, endpoints, and statistical power. |
| Manufacturing | Contract-manufacturing model; no owned plant | Vendor quality, scale-up, and supply continuity. |
| Commercial stage | Not established; partner or internal launch possible | Approval, pricing, reimbursement, and physician adoption. |
Which clinical programs matter most?
During 2026, CalciMedica concentrated resources on acute pancreatitis and pulmonary hypertension. Auxora’s PAH Phase 1b study is intended to provide rapid human proof of concept and de-risk CM5480. Acute kidney injury retains optionality, but KOURAGE’s mortality imbalance and redesign make its path less predictable.
What does the Auxora evidence base contribute?
CARPO evaluated 214 patients with acute pancreatitis and systemic inflammatory response syndrome. CalciMedica reported no new-onset severe respiratory failure in the medium- and high-dose groups, described as a statistically significant 100% reduction versus placebo, plus a 1.640 stratified win ratio in the high-dose arm. These signals support the official acute pancreatitis program, but pivotal evidence remains necessary.
CARDEA reported a 56% relative reduction in 30-day mortality in severe COVID-19. A post-hoc subgroup of 38 patients with kidney injury showed a 62.7% relative reduction. These findings strengthen biological rationale but cannot replace a prospectively powered study.
Why could CM5480 change the business model?
Auxora is an intravenous hospital drug; CM5480 is designed for chronic oral dosing. If CRAC inhibition works in pulmonary hypertension, CM5480 could support longer treatment duration and recurring economics. The company’s pulmonary hypertension materials emphasize vascular remodeling and right-ventricular function as potential differentiators.
| Program | Asset / route | Latest official status | Value-defining next step |
|---|---|---|---|
| Pulmonary arterial hypertension | Auxora / IV | Phase 1b planned, June 2026 strategy | Human proof-of-concept data anticipated mid-2027. |
| Pulmonary hypertension | CM5480 / oral | IND-enabling development | IND clearance anticipated mid-2027. |
| Acute pancreatitis | Auxora / IV | Phase 2b CARPO completed | FDA feedback on potential pivotal program expected Q3 2026. |
| Acute kidney injury with AHRF | Auxora / IV | KOURAGE discontinued; protocol amendment reviewed | Determine whether and how to restart development. |
What do Q1 2026 results actually show?
The latest filed period is the quarter ended March 31, 2026. The Q1 2026 Form 10-Q reported no revenue, $5.6 million of operating expense, and $4.9 million of operating cash use. Net income of $5.0 million came from non-cash fair-value gains, not commercial profitability.
Why is the reported net income misleading?
Operating loss was $5.6 million in Q1 2026. Other income of $10.6 million included a $10.8 million fair-value gain, partly offset by $0.3 million of interest expense. The first-quarter results release therefore requires an operating-versus-accounting distinction: remeasurement gains do not fund trials.
What does the balance sheet say about financial risk?
At March 31, 2026, assets were $8.6 million and liabilities $9.7 million, producing a $1.1 million stockholders’ deficit. The promissory note carried $6.7 million, while accumulated deficit reached $184.4 million. These figures explain why liquidity and financing terms matter more than quarterly EPS.
| Metric | Q1 2026 | Q1 2025 / prior balance | Interpretation |
|---|---|---|---|
| R&D expense | $3.485M | $4.224M | Down 17.5%, reflecting lower trial and CMC activity. |
| G&A expense | $2.126M | $2.273M | Down 6.5%, mainly lower personnel costs. |
| Operating loss | $(5.611)M | $(6.497)M | Core business remained loss-making. |
| Fair-value gain | $10.800M | $1.700M | Non-cash remeasurement drove reported profit. |
| Net income (loss) | $4.976M | $(5.042)M | Not a useful proxy for operating performance. |
| Operating cash flow | $(4.856)M | $(4.878)M | Cash burn was nearly unchanged year over year. |
| FY2025 measure | Amount | Research implication |
|---|---|---|
| R&D expense | $15.234M | Core scientific reinvestment rose 5% from FY2024. |
| G&A expense | $7.887M | Administrative spending declined 19% from FY2024. |
| Net loss | $(29.562)M | Included $6.0M of unfavorable fair-value adjustments. |
| Operating cash flow | $(21.178)M | Best measure of annual funding consumption. |
| Cash, equivalents, investments | $13.012M | Insufficient to fund development through approval. |
How did CalciMedica’s strategy evolve?
CalciMedica’s strategic history is a narrowing process: a broad calcium-signaling platform became a focused clinical portfolio, then a public company through the March 2023 reverse merger with Graybug. Subsequent financings and trial results repeatedly reshaped which indications could be funded.
Which turning points explain the current company?
-
2006Operations began. The long private-company period built CRAC-channel chemistry, patents, and disease biology before public listing.
-
2020–2022Auxora advanced through Phase 2 acute-care studies, including severe COVID-19 pneumonia and early acute-pancreatitis work, establishing human exposure and a safety database.
-
March 2023Private CalciMedica merged with Graybug Vision; the surviving public company adopted the CalciMedica name and CALC ticker. The reverse merger supplied approximately $29.4 million of cash and investments.
-
June 2024CARPO Phase 2b topline data in acute pancreatitis supported continued work toward a potential pivotal program.
-
2025The company borrowed $10.0 million gross from Avenue and spent $15.2 million on R&D while advancing KOURAGE and CM5480.
-
January 2026KOURAGE was discontinued after an independent committee identified a mortality imbalance requiring study-design reevaluation, although reviews did not identify drug-related toxicity.
-
June 2026FDA review produced no comments on the amended KOURAGE submission, and a new financing funded a focused pulmonary-hypertension strategy into the second half of 2027.
The reverse merger supplied approximately $29.4 million of cash, equivalents, and investments and created a public financing vehicle. It did not change the underlying model: each program still requires external capital until approval, partnership, or sustainable revenue.
What gives the CRAC channel platform a competitive edge?
CalciMedica’s prospective moat is not scale. It rests on selective Orai1 inhibition, intravenous and oral formulations, human exposure data, indication-specific development knowledge, and patents. Those assets may shorten learning cycles, but larger competitors retain superior capital, infrastructure, and commercialization reach.
How strong is the intellectual-property position?
At December 31, 2025, CalciMedica reported four issued U.S. composition patents and more than 60 issued patents worldwide for Auxora-related compounds. Composition claims generally expire from 2031 to 2036 before extensions. Acute-pancreatitis method rights included two issued U.S. patents and more than 30 worldwide, with issued and pending coverage expected into 2031-2046.
Which competitors and substitutes matter?
The 10-K names Rhizen Pharmaceuticals, Vivreon Biosciences, Medshine Discovery, Eldec Pharmaceuticals, and ChemiCare as CRAC-channel developers. In acute kidney injury, broader substitutes include agents such as Novartis’s TIN816 and AstraZeneca’s AZD-4144. Competition therefore comes from both mechanism peers and alternative disease pathways.
| Competitive factor | CalciMedica position | Constraint |
|---|---|---|
| Mechanism | Upstream CRAC/Orai1 inhibition with inflammatory and tissue-protection rationale | Mechanistic breadth must translate into reproducible clinical benefit. |
| Clinical experience | More than 350 patients evaluated across Auxora trials by June 2026 | Experience spans different diseases and does not equal pivotal evidence. |
| Formulation range | IV Auxora plus oral CM5480 | CM5480 had not entered human testing as of June 2026. |
| Patent estate | Composition, use, formulation, and synthesis rights | Patent challenges, design-arounds, and finite terms remain possible. |
| Operating scale | Focused 16-person organization | Competitors possess much greater capital and commercialization capacity. |
How financially strong is CalciMedica after the June 2026 financing?
The June 2026 private placement improved liquidity but did not make CalciMedica self-funding. Before closing, March cash was $8.2 million and Q1 operating cash use was $4.9 million. The June 2026 financing announcement disclosed about $15 million upfront and potential aggregate proceeds of roughly $49 million if both warrant series are exercised.
What does the runway really cover?
Management said upfront proceeds should extend runway into the second half of 2027. That plan funds PAH Phase 1b data and CM5480 IND work, not approval or commercialization. Unexercised warrants are contingent financing, so further capital or a partner will still be needed.
How should dilution and debt be interpreted?
The placement was materially dilutive. Official filings indicate about 14.94 million common shares were issued versus 15.80 million outstanding on May 6, 2026; pre-funded warrants covered additional units. Series A and B warrants may add more shares. Avenue debt also matters: the March note balance was $6.7 million, with principal payments scheduled from October 2026.
Who owns CalciMedica and how does governance affect the story?
Before the June placement, ownership was concentrated. The 2025 Form 10-K/A reported that directors and executive officers beneficially owned 41.64% as of March 31, 2026, based on 15.746 million outstanding shares and exercisable securities. That alignment also conferred meaningful influence over financing and strategy.
What did the pre-financing ownership structure look like?
| Holder / group | Beneficial shares | Stake | Governance relevance |
|---|---|---|---|
| Directors and executive officers, 11 persons | 7,677,052 | 41.64% | High collective influence and substantial equity alignment. |
| Sanderling Ventures affiliates | 2,446,661 | 15.50% | Long-standing venture sponsor with board connection through Fred Middleton. |
| Alafi Capital | 1,583,153 | 10.05% | Major legacy investor that also participated in the June financing. |
| Avenue affiliates | 1,359,553 | 7.95% | Lender and equity-linked holder; capital-structure interests matter. |
| Jorey Chernett | 1,134,847 | 7.21% | Meaningful individual beneficial holder. |
| Soleus Capital affiliates | 1,075,856 | 6.67% | Specialist healthcare capital in the pre-financing register. |
How did the June financing change the investor profile?
The placement reset the capitalization. Management, directors, and related holders above 5% subscribed for about 6.909 million units, signaling commitment. Yet issuing nearly as many common shares as were previously outstanding reduced legacy percentages, while warrants introduced further dilution and stockholder-approval decisions.
Which opportunities and risks could change the outcome?
CalciMedica combines platform upside with concentrated clinical risk. CRAC inhibition could address diseases where inflammation, vascular remodeling, and organ injury interact. The counterpoint is that a plausible mechanism may not produce sufficiently strong, safe, and reproducible outcomes, while each additional test consumes capital.
Where is the most credible upside?
Pulmonary hypertension creates a paired strategy: Auxora can test the mechanism in hospitalized patients, while CM5480 targets chronic dosing. Acute pancreatitis offers a more mature dataset and an estimated 300,000 U.S. hospitalizations annually with no approved disease-modifying therapy. Either success would validate the platform beyond one indication.
Which risks are most material?
Clinical design and safety are the leading risks. KOURAGE’s mortality imbalance did not yield evidence of drug-related toxicity, and the June FDA update reported no agency comments or questions on the amendment and 107-patient safety package. Still, baseline imbalance and endpoint design can invalidate a trial without proving toxicity.
What matters most for valuation and future monitoring?
A near-term revenue DCF is inappropriate because CalciMedica has no approved product. A risk-adjusted pipeline model should estimate patient population, net price, penetration, launch timing, margins, success probability, remaining development cost, central overhead, financing needs, and dilution for each indication.
Which metrics should researchers track next?
How should a DCF or comparable analysis be structured?
Model Auxora in acute pancreatitis, Auxora in PAH, and CM5480 separately. Use indication-specific probabilities and launch dates, subtract remaining program costs, and discount for time and financing risk. Because June 2026 changed the share count and warrants may expand it again, test fully diluted scenarios. Peer comparisons should emphasize development stage, human evidence, runway, partnerships, and enterprise value—not sales or earnings multiples.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
